The example everyone reaches for when they want to show that pharmacogenomics changed practice — and it did. Test before the first dose, do not prescribe if positive, and a reaction people used to fear became rare.
HLA-B*57:01 carriage is strongly associated with abacavir hypersensitivity, a reaction that can be fatal on re-exposure. CPIC issued guidance in 2012 and confirmed in its 2014 update that the recommendation was unchanged: screen before the first dose and do not prescribe abacavir to a carrier. This is a pre-prescription safety test performed by clinical HLA typing, and it is the example most often given of pharmacogenomics changing practice — the reaction became uncommon where screening was adopted.
CPIC Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update (Clin Pharmacol Ther 2014, PMID 24561393).
These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.
HLA-B · rs114985235
Read more →HLA-B · rs2523590
Read more →HLA-B · rs2395029
Read more →